Although the detailed mechanisms involved in bevacizumab-mediated inhibition of MMP-3 and MMP-13 expression and pterygium fibroblast migration are currently unknown, the present study suggests that bevacizumab could make an important contribution to the management of pterygia. This evidence concerns the gene MMP3 and pterygium.